THOMPSON CANCER SURVIVAL CENTER TO TAKE CANCER PROGRAM TO THE NEXT LEVEL WITH PURCHASE OF ELEKTA INFINITY TREATMENT SYSTEM

THOMPSON CANCER SURVIVAL CENTER TO TAKE CANCER PROGRAM TO THE NEXT LEVEL WITH
PURCHASE OF ELEKTA INFINITY TREATMENT SYSTEM

Press Release 
Stockholm, Sweden, September 18, 2008

Thompson Cancer Survival Center (TCSC, Knoxville, Tennessee) has placed an order
for Elekta Infinity, reaffirming their long-term commitment to deliver the most
advanced radiation therapy treatments. The addition of Elekta Infinity, a linear
accelerator optimized for Volumetric Modulated Arc Therapy (VMAT) will
complement the center's decade-long plan to improve patient outcomes.


Chester Ramsey, Ph.D., director of medical physics at TCSC expects the time
savings with Elekta VMAT, a new treatment that targets tumors with high doses of
radiation while protecting healthy tissue, to be dramatic. “With fixed-gantry
IMRT delivery on other linear accelerators, it currently takes 7 to 15 minutes
to treat most of our IMRT patients. We estimate that VMAT treatment delivery
times with Elekta Infinity will be reduced by at least 50 percent, without
compromising treatment quality.”
“At TCSC, clinicians and researchers began using single rotation, constant dose
rate volume modulated arc therapy more than 10 years ago,” explains Ramsey. “The
added capabilities of Elekta Infinity, such as simultaneous control of gantry
rotation speed, collimator rotation and variable dose rate will advance our
cancer treatment program to a new level.”

TCSC currently treats 100-150 patients per day at three locations. Dr. Ramsey
expects to treat up to 40 patients each day with Elekta Infinity, about half of
which will be VMAT treatments for prostate, head and neck, lung, esophagus and
brain cancers. 

In addition to Elekta Infinity, TCSC also is scheduled to install an Elekta
Synergy® linear accelerator. Elekta Synergy is an advanced multi-functional
linear accelerator that enables clinicians to image and treat patients
simultaneously.

Clinical information from all treatment systems will be streamlined with MOSAIQ®
image-enabled oncology EMR, already in use at TCSC. MOSAIQ integrates patient
information and charts from initial diagnosis and staging through scheduling,
planning, treatment and subsequent follow-up, maximizing efficiency and
minimizing patient waiting times.

Dr. Ramsey says the new additions at TCSC will provide patients with a higher
standard of cancer care than ever before. “The clinicians and researchers at
TCSC are extremely excited about our new relationship with Elekta,” he adds.


For further information, please contact:

Media: 
Michelle Lee, Elekta, Inc
Tel: 1- 770-670-2447, e-mail: michelle.lee@elekta.com

Inverstors:
Lena Schattauer, Investor Relations, Elekta AB
Tel: +46 8 587 257 22, +46 70 595 51 00, e-mail: lena.schattauer@elekta.com   


About Elekta

Elekta is a human care company pioneering significant innovations and clinical
solutions for treating cancer and brain disorders. The company develops
sophisticated state of the art tools and treatment planning systems for
radiation therapy and radiosurgery, as well as workflow enhancing software
systems across the spectrum of cancer care.

Stretching the boundaries of science and technology, providing intelligent and
resource-efficient solutions that offer confidence to both healthcare providers
and patients, Elekta aims to improve, prolong and even save patient lives,
making the future possible today.

Today, Elekta solutions in oncology and neurosurgery are used in over 5,000
hospitals globally, and every day more than 100,000 patients receive diagnosis,
treatment or follow-up with the help of a solution from the Elekta Group.

Elekta employs around 2,500 employees globally. The corporate headquarter is
located in Stockholm, Sweden, and the company is listed on the Nordic Exchange
under the ticker EKTAb. For more information about Elekta, please visit
www.elekta.com.